TNON

Tenon is a $3.3M-market-cap medical device micro-cap that, despite a decent 59.8% gross margin and steady top-line growth (revenue $3.94M, +20.4% YoY, up from $160K in FY2021), has never come close to viability. FY2025 operating income was -$12.8M on $3.94M of revenue — an operating margin of -324% — and the loss is structural, not a one-off: the company states it has 'incurred net losses since our inception in 2012' and carries an $81.3M accumulated deficit. Revenue is simply too small relative to the fixed cost of running an FDA-cleared commercial device business (Catamaran plus the newly acquired SImmetry+ system), and there is no visible path to that gap closing.

The balance sheet is the disqualifier. Operating cash flow was -$10.7M in FY2025 against just $3.76M of cash (itself down 42.5% YoY) — well under half a year of runway at the current burn. The company concedes it has 'financed our operations primarily through public equity offerings, private placements... and sales of our product,' and the mechanics of that financing are punishing: shares outstanding grew 102.3% in a single year, current liabilities jumped 71.9%, and equity fell 15.6%. On top of the 11.3M shares out sits an enormous warrant/preferred overhang — Series C/D/E warrants alone total roughly 6.5M shares at $1.25–$2.00, plus a November 2025 private placement layering on 2.2M more warrants at $1.16, and ~1.8M preferred conversion shares. Against 11.3M shares, that overhang is dilutive on the order of the entire existing float.